Stockscreener 앱 받기
4.42
3.49%
-0.16
시간 외 거래:
4.48
0.06
+1.36%
Minerva Neurosciences Inc 주식(NERV)의 최신 뉴스
NERV Upgraded by Jefferies -- Price Target Raised to $10.00 - GuruFocus
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway By Investing.com - Investing.com Canada
Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants - Stock Titan
Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants - Stock Titan
Minerva Neurosciences Elevates Aliquo to Accounting Leadership - TipRanks
Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role - Stock Titan
HC Wainwright Has Bearish Estimate for NERV Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen - MarketBeat
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com - Investing.com Nigeria
Minerva Neurosciences Q2 adjusted EPS beats estimates on warrant gain - scanx.trade
Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates - TradingView
Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary - TradingView
Minerva Neurosciences (NASDAQ: NERV) logs $107.9M loss but holds $75.4M cash - Stock Titan
Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M - TradingView
Minerva Neurosciences: Q2 Earnings Snapshot - marketscreener.com
Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues - Quiver Quantitative
Minerva Neurosciences (Nasdaq: NERV) swings to Q2 profit on warrant gain - Stock Titan
Minerva's schizophrenia trial is designed to enroll 380 patients - Stock Titan
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
Janus Henderson Group PLC Increases Stock Position in Minerva Neurosciences, Inc $NERV - MarketBeat
Form 4 Minerva Neurosciences Inc For: 3 August By Investing.com - Investing.com Nigeria
Minerva Neurosciences (NERV) awards options tied to Phase 3 trial - Stock Titan
NERV Q2'26 Earnings: EPS estimate is (0.19) USD - TradingView
Seven Fleet Capital Management LP Makes New Investment in Minerva Neurosciences, Inc $NERV - MarketBeat
NERV Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NERV|Minerva Neurosciences Inc|Price:4.205| - TradingKey
Minerva Neurosciences Inc (NERV) Cash Flow - TradingKey
Minerva Neurosciences Inc (NERV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Minerva Neurosciences Inc (NERV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Minerva Neurosciences Inc (NERV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Minerva Neurosciences Inc Revenue Breakdown – FWB:4MNA - TradingView
Minerva Neurosciences Inc (NERV) Institutional Confidence - TradingKey
NERV Options Chain — NASDAQ:NERV - TradingView
NERV Options Volatility — NASDAQ:NERV - TradingView
ETFs Investing in Minerva Neurosciences Inc Stocks - TradingView
FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neu - GuruFocus
Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV) - Stock Titan
Minerva Neurosciences (NERV) Slides 3.15% as Stock Tests Key Support at $4.52Iron Condor Alert - dars.gov.et
Minerva Neurosciences (NERV) Hovers Near Support as Trading Remains SubduedTICK Divergence - dars.gov.et
NERVMinerva Neurosciences Inc Options - Finviz
NERV News | MINERVA NEUROSCIENCES INC (NASDAQ:NERV) - ChartMill
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Value Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Value Benchmark Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell Microcap Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell 3000E Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Value Benchmark - marketscreener.com
Price to sales forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Minerva Neurosciences Inc Actuals & Estimates (NASDAQ:NERV) - TradingView
NERV Forecast — Price Target — Prediction for 2027 - TradingView
Minerva Neurosciences Inc Actuals & Estimates (SWB:4MNA) - TradingView
Minerva Neurosciences Inc Actuals & Estimates (FWB:4MNA) - TradingView
Minerva Neurosciences Inc Actuals & Estimates (BOATS:NERV) - TradingView
Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis - TradingKey
4MNA Forecast — Price Target — Prediction for 2027 - TradingView
1.80%
1.77%
자본화:
|
볼륨(24시간):